Crossmark

Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients

Crossref DOI link: https://doi.org/10.1186/s13014-023-02310-8

Published Online: 2023-07-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Li, Lu

Chen, Lu

Yan, Lu

Guo, Yueqian

Li, Fang

Fan, Ming

Lan, Mei

Lai, Xin

Zhou, Jie

Huang, Yecai

Xu, Peng

Lang, Jinyi

Feng, Mei
Funding

Funding for this research was provided by:

Sichuan Province Science and Technology Support Program (2021JDRC0146)

Chinese Medical Association Radiation Oncology Therapy Branch Immunoradiotherapy Research Fund Project (Z-2017-24-2020)

Oncology Medicine and Engineering Innovation Fund (ZYGX2021YGCX006)
License Information

Text and Data Mining valid from 2023-07-04

Version of Record valid from 2023-07-04
More Information

Article History

Received: 8 October 2022

Accepted: 26 June 2023

First Online: 4 July 2023

Declarations

:

: The study protocol and all amendments were approved by the institutional review boards or ethics committees of all participating sites (SCCHEC-02–2020-018). Written informed consent was obtained from all subjects involved in the study.

: Written informed consent for publication of their clinical details and/or clinical images was obtained from the patient/parent/guardian/ relative of the patient.

: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Document is current

Any future updates will be listed below